ViroPharma, Inc.’s HCV-796 for hepatitis C virus infection has been granted fast track designation by the FDA. HCV-796, an orally dosed non-nucleoside hepatitis C viral polymerase inhibitor that interferes with the replication of hepatitis C virus (HCV), is currently in Phase II trials and is being co-developed with Wyeth Pharmaceuticals. “The receipt of fast track designation for HCV-796 is an important regulatory step forward as we continue to work closely with the FDA and our...